ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,473Medicare Part D Prescriptions Filled, Including Refills

Rank: 19 out of 559

$548K Total Retail Price of All Prescriptions

Rank: 25 out of 559

610 Patients Receiving at Least One Drug in Part D
79%Patients 65 Years and Older
35% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New Mexico
Lower avg

Schedule Two
Controlled Substances

10% of this provider’s 610 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

15% of this provider’s 610 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

1% of this provider’s 8,095 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

18% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$48 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

19 is the average number of prescriptions (including refills) per patient, compared to an average of 14.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New Mexico
LISINOPRIL 604 511 1 1
LEVOTHYROXINE SODIUM 591 426 2 2
SIMVASTATIN 494 402 3 3
METFORMIN HCL 364 298 4 5
OMEPRAZOLE 338 248 5 4
LOVASTATIN 305 262 6 10
AMLODIPINE BESYLATE 297 249 7 6
GABAPENTIN 286 166 8 9
HYDROCHLOROTHIAZIDE 278 196 9 8
HYDROCODONE-ACETAMINOPHEN 275 169 S3 10 7
ATENOLOL 229 191 11 15
METOPROLOL TARTRATE 189 175 12 12
FUROSEMIDE 186 156 13 11
LISINOPRIL-HYDROCHLOROTHIAZIDE 183 132 14 18
LOSARTAN POTASSIUM 160 135 15 14
ENDOCET 153 87 S2 16 105
RANITIDINE HCL 136 80 17 26
ALENDRONATE SODIUM 124 83 18 13
TRAZODONE HCL 123 77 19 28
PROAIR HFA 119 53 20 29
ZOLPIDEM TARTRATE 118 89 21 17
ALLOPURINOL 118 109 21 34
DOXAZOSIN MESYLATE 114 94 23 43
POTASSIUM CHLORIDE 113 103 24 23
OXYCODONE HCL 110 35 S2 25 32
FLUTICASONE PROPIONATE 104 63 26 22
CRESTOR 95 74 27 33
GLIPIZIDE 91 70 28 31
PANTOPRAZOLE SODIUM 90 51 29 41
CITALOPRAM HBR 85 61 30 21
FLUOXETINE HCL 83 57 31 37
JANUVIA 76 63 32 50
TRAMADOL HCL 74 54 33 27
BACLOFEN 72 34 34 90
AMITRIPTYLINE HCL 71 26 R 35 58
TRIAMTERENE-HCTZ 70 60 36 47
AZITHROMYCIN 66 44 37 39
ATORVASTATIN CALCIUM 64 29 38 20
IBUPROFEN 63 17 39 30
OXYBUTYNIN CHLORIDE 61 32 40 62
SULFAMETHOXAZOLE-TRIMETHOPRIM 59 34 41 96
ACETAMINOPHEN-CODEINE 58 35 S3 42 83
GLYBURIDE 58 51 R 42 45
TAMSULOSIN HCL 56 40 44 25
VENLAFAXINE HCL ER 56 42 44 111
DONEPEZIL HCL 55 55 46 36
FENTANYL 54 32 S2 47 88
ADVAIR DISKUS 52 42 48 46
NAMENDA 51 51 49 56
CYMBALTA 50 21 50 78
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 20, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.